PMID- 36131924
OWN - NLM
STAT- MEDLINE
DCOM- 20220923
LR  - 20220926
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Exploration of shared TF-miRNA‒mRNA and mRNA-RBP-pseudogene networks in type 2 
      diabetes mellitus and breast cancer.
PG  - 915017
LID - 10.3389/fimmu.2022.915017 [doi]
LID - 915017
AB  - Type 2 diabetes mellitus (T2DM) has been confirmed to be closely associated with 
      breast cancer (BC). However, the shared mechanisms between these diseases remain 
      unclear. By comparing different datasets, we identified shared differentially 
      expressed (DE) RNAs in T2DM and BC, including 427 mRNAs and 6 miRNAs from the 
      GEO(Gene Expression Omnibus) database. We used databases to predict interactions 
      to construct two critical networks. The transcription factor (TF)-miRNA‒mRNA 
      network contained 236 TFs, while the RNA binding protein (RBP)-pseudogene-mRNA 
      network showed that the pseudogene S-phase kinase associated protein 1 pseudogene 
      1 (SKP1P1) might play a key role in regulating gene expression. The shared mRNAs 
      between T2DM and BC were enriched in cytochrome (CYP) pathways, and further 
      analysis of CPEB1 and COLEC12 expression in cell lines, single cells and other 
      cancers showed that they were strongly correlated with the survival and prognosis 
      of patients with BC. This result suggested that patients with T2DM presenting the 
      downregulation of CPEB1 and COLEC12 might have a higher risk of developing BC. 
      Overall, our work revealed that high expression of CYPs in patients with T2DM 
      might be a susceptibility factor for BC and identified novel gene candidates and 
      immune features that are promising targets for immunotherapy in patients with BC.
CI  - Copyright (c) 2022 Tong, Wenze, Libing, Yuchen, Hejia, Xi, Xiongyi, Guoguo and Min.
FAU - Tong, Wu
AU  - Tong W
AD  - The First Clinical School, Southern Medical University, Guangzhou, China.
FAU - Wenze, Gu
AU  - Wenze G
AD  - The First Clinical School, Southern Medical University, Guangzhou, China.
FAU - Libing, Hong
AU  - Libing H
AD  - The Second Clinical School, Southern Medical University, Guangzhou, China.
FAU - Yuchen, Cao
AU  - Yuchen C
AD  - The Second Clinical School, Southern Medical University, Guangzhou, China.
FAU - Hejia, Zhao
AU  - Hejia Z
AD  - The Second Clinical School, Southern Medical University, Guangzhou, China.
FAU - Xi, Guo
AU  - Xi G
AD  - The Second Clinical School, Southern Medical University, Guangzhou, China.
FAU - Xiongyi, Yang
AU  - Xiongyi Y
AD  - The Second Clinical School, Southern Medical University, Guangzhou, China.
FAU - Guoguo, Yi
AU  - Guoguo Y
AD  - Department of Ophthalmology, The Sixth Affiliated Hospital of Sun-Yat-Sen 
      University Guangzhou, Guangdong, China.
FAU - Min, Fu
AU  - Min F
AD  - Department of Ophthalmology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou, Guangdong, China.
LA  - eng
PT  - Journal Article
DEP - 20220905
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Cytochromes)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (S-Phase Kinase-Associated Proteins)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - *Breast Neoplasms/genetics
MH  - Cytochromes/genetics/metabolism
MH  - *Diabetes Mellitus, Type 2/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Regulatory Networks
MH  - Humans
MH  - *MicroRNAs/genetics/metabolism
MH  - Pseudogenes
MH  - RNA, Messenger/genetics/metabolism
MH  - RNA-Binding Proteins/metabolism
MH  - S-Phase Kinase-Associated Proteins/genetics/metabolism
MH  - Transcription Factors/genetics/metabolism
PMC - PMC9484524
OTO - NOTNLM
OT  - BC
OT  - RNA methylation
OT  - ceRNA
OT  - immune microenvironment
OT  - miRNA-TF-mRNA network
OT  - rT2DM
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/23 06:00
MHDA- 2022/09/24 06:00
PMCR- 2022/01/01
CRDT- 2022/09/22 03:29
PHST- 2022/04/07 00:00 [received]
PHST- 2022/08/01 00:00 [accepted]
PHST- 2022/09/22 03:29 [entrez]
PHST- 2022/09/23 06:00 [pubmed]
PHST- 2022/09/24 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.915017 [doi]
PST - epublish
SO  - Front Immunol. 2022 Sep 5;13:915017. doi: 10.3389/fimmu.2022.915017. eCollection 
      2022.